China Net Finance, November 13th - BeiGene's third quarter report has recently been released. From January to September, BeiGene achieved a revenue of 19.136 billion yuan, a year-on-year increase of 48.63%; The net profit attributable to shareholders of the listed company was 3.687 billion yuan, and the extent of losses narrowed compared to the same period last year; The net cash flow generated from operating activities was -1.841 billion yuan.
For the growth in revenue, BeiGene stated that it was mainly due to the company's self-developed product, Bayeuze&Co; reg; And Baize An& reg; And the sales growth of authorized products from Anjin. In addition, the company regained the rights to Osipilimumab and Baize An during the same period last year; reg; After obtaining all global commercial rights, the remaining deferred income related to the cooperation was recognized, resulting in a corresponding increase in operating income for the same period last year.
Taking the third quarter as an example, Baiyue Ze& reg; Global sales totaled 4.914 billion yuan, a year-on-year increase of 91.1%, further consolidating its leadership position in the field of hematological oncology; Baize An& reg; The total sales revenue was 1.169 billion yuan, a year-on-year increase of 11.7%.
From the perspective of product market layout, Baiyue Ze has been approved for multiple indications in over 70 markets worldwide; Baize An& reg; It has been approved in 42 countries and regions. In October of this year, Baize An& reg; It has been commercialized in the United States for second-line treatment of esophageal squamous cell carcinoma (ESCC) patients, and in the first batch of European countries for second-line treatment of ESCC patients and first - and second-line treatment of non-small cell lung cancer (NSCLC) patients.
Along with revenue growth, BeiGene's sales expenses, management expenses, and research and development expenses for the first three quarters were 6.348 billion yuan, 3.153 billion yuan, and 10.166 billion yuan, respectively, all showing growth compared to the same period last year. As of the end of September, BeiGene had a monetary fund of 12.245 billion yuan, with accounts receivable and inventory of 3.99 billion yuan and 3.028 billion yuan respectively, and an asset liability ratio of 40.84%.
It is worth noting that BeiGene raised 22.16 billion yuan through an IPO when it listed on the Science and Technology Innovation Board in 2021, with a net fundraising amount of 21.63 billion yuan after deducting issuance expenses, exceeding the fundraising limit by 2 billion yuan. Recently, BeiGene announced that its board of directors has agreed to permanently supplement its working capital with 489 million yuan of over raised funds. BeiGene stated that using some of the excess funds to permanently supplement working capital can meet the company's working capital needs, improve the efficiency of the use of raised funds, reduce financial costs, and further safeguard the interests of the company and shareholders.